Sermorelin
Also known as: GHRH(1-29)-NH2 · GRF(1-29) · Sermorelin acetate · Geref
Sermorelin binds GHRH receptors on pituitary somatotrophs, stimulating synthesis and pulsatile release of GH. As the native GHRH(1-29) sequence, it is rapidly degraded by dipeptidyl aminopeptidase IV (DPP-IV) giving a short half-life, which means it must be dosed more frequently...
What It Is
Sermorelin binds GHRH receptors on pituitary somatotrophs, stimulating synthesis and pulsatile release of GH. As the native GHRH(1-29) sequence, it is rapidly degraded by dipeptidyl aminopeptidase IV (DPP-IV) giving a short half-life, which means it must be dosed more frequently than modified analogs (CJC-1295 no DAC). However, this physiological half-life preserves natural pulsatile GH secretion. Sermorelin restores declining GH pulse amplitude in adults with age-related GH insufficiency. It upregulates GHRH receptor expression with chronic use, potentially improving long-term GH axis responsiveness.
Supplies Needed
Reconstitution solvent
Subcutaneous injection
Sterilization
Storage
Store at 2-8C (refrigerator) or -20C for research peptide. Protect from light.
Refrigerate at 2-8C; use within 30 days.
This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.
Dosing Protocols
Timing: Before bed, fasted. Bedtime injection maximizes natural nocturnal GH pulse; simple once-daily protocol
↓ Apply these values to the reconstitution calculatorTiming: Before bed; second dose morning fasted if twice daily. Combine with Ipamorelin at each injection for enhanced GH pulse; twice-daily maximizes GH production
↓ Apply these values to the reconstitution calculatorTiming: Morning fasted and before bed. Long-term use is the primary advantage of Sermorelin over stronger analogs - very safe for extended use
↓ Apply these values to the reconstitution calculatorWeekly Timeline
| Week | Expected Effects |
|---|---|
| Week 1 | Improved sleep depth; early GH pulse restoration |
| Week 2 | Better morning energy; improved hydration; early body composition changes |
| Week 4 | Noticeable body composition improvements; improved skin quality |
| Week 12 | Significant GH axis restoration; lean mass improvement; anti-aging benefits accumulating |
| Week 24 | Maximum long-term GH optimization; sustained improvements in body composition, sleep, and skin |
Reconstitution Calculator
1 unit on U-100 syringe = 0.01 mL · Always label your vial after reconstitution
Injection Technique & Reconstitution
- Remove flip-top cap from the vial
- Swab rubber stopper with alcohol swab and allow to dry
- Draw 3 mL bacteriostatic water into syringe
- Inject slowly down the vial wall
- Gently swirl until dissolved
- Label with reconstitution date; refrigerate at 2-8C
Use our free peptide calculator to get the exact syringe units for your vial size and dose.
Mechanism of Action
Sermorelin binds GHRH receptors on pituitary somatotrophs, stimulating synthesis and pulsatile release of GH. As the native GHRH(1-29) sequence, it is rapidly degraded by dipeptidyl aminopeptidase IV (DPP-IV) giving a short half-life, which means it must be dosed more frequently than modified analogs (CJC-1295 no DAC). However, this physiological half-life preserves natural pulsatile GH secretion. Sermorelin restores declining GH pulse amplitude in adults with age-related GH insufficiency. It upregulates GHRH receptor expression with chronic use, potentially improving long-term GH axis responsiveness.
Key Research Papers
Demonstrated significant improvements in lean body mass and fat mass reduction in GH-deficient adults treated with Sermorelin, establishing its body composition benefits.
View on PubMed →Stacks Well With
GHRH (Sermorelin) + GHS-R1a (Ipamorelin) synergistic dual-receptor activation - the most physiological and safest GH optimization stack for long-term use.
GH axis optimization (Sermorelin) combined with tissue repair and gut healing (BPC-157) for comprehensive recovery and anti-aging protocol.
Frequently Asked Questions
Yes - Sermorelin (Geref) was FDA approved for GH deficiency diagnosis and treatment in children. It was withdrawn from the US market in 2008 for commercial reasons, not safety concerns. It remains available through compounding pharmacies.
Sermorelin has a shorter half-life (native sequence, rapidly degraded) compared to CJC-1295 no DAC. This means it requires more frequent dosing and produces smaller GH pulses per dose. However, Sermorelin's long safety track record and FDA history make it preferred for conservative long-term use.
Legal Status by Region
This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.